Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GB-0895 adjunctive therapy in severe uncontrolled asthma
PACTR202606702953350Phase 3Not yet recruiting
- Sponsor
- Generate Biomedicines
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing GB-0895 adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Clinically significant asthma exacerbations over 52 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GB-0895
03
Conditions
asthma
Beyond the preview
Go deeper on PACTR202606702953350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606702953350.